Summary by Moomoo AI
On January 8, 2024, Novavax, Inc. updated investors, reaffirming its guidance for the full year 2023 expenses to be between $1.15 billion and $1.25 billion. The company is currently finalizing its financial results for the year ended December 31, 2023, and has stated that the preliminary financial data provided is based on the information available and may be subject to change. The data has not been audited or reviewed by Ernst & Young LLP, the company's independent registered public accounting firm, or any other independent accountants. Novavax cautions that the actual results may differ materially from the preliminary data and advises investors not to place undue reliance on this preliminary information. Additionally, Novavax presented strategic and business updates at the 42nd Annual J.P. Morgan Healthcare Conference, with the presentation available on the company's website. The company also included forward-looking statements in its report and presentation, warning that actual results could vary significantly due to various risks and uncertainties.